WO2003029278A3 - Il10-r : modulateurs de l'activation des lymphocytes - Google Patents

Il10-r : modulateurs de l'activation des lymphocytes Download PDF

Info

Publication number
WO2003029278A3
WO2003029278A3 PCT/US2002/031619 US0231619W WO03029278A3 WO 2003029278 A3 WO2003029278 A3 WO 2003029278A3 US 0231619 W US0231619 W US 0231619W WO 03029278 A3 WO03029278 A3 WO 03029278A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
cell activation
present
modulators
lymphocyte activation
Prior art date
Application number
PCT/US2002/031619
Other languages
English (en)
Other versions
WO2003029278A2 (fr
Inventor
Peter Chu
Congfen Li
Charlene X Liao
Jorge Pardo
Original Assignee
Rigel Pharmaceuticals Inc
Peter Chu
Congfen Li
Charlene X Liao
Jorge Pardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc, Peter Chu, Congfen Li, Charlene X Liao, Jorge Pardo filed Critical Rigel Pharmaceuticals Inc
Priority to AU2002341948A priority Critical patent/AU2002341948A1/en
Publication of WO2003029278A2 publication Critical patent/WO2003029278A2/fr
Publication of WO2003029278A3 publication Critical patent/WO2003029278A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la régulation de l'activation des lymphocytes T. La présente invention concerne notamment des acides nucléiques codant l'IL10-R, par exemple, l'IL10-Rα. L'invention concerne également des méthodes d'identification et d'utilisation d'agents, notamment de petites molécules organiques, d'anticorps, de peptides, de peptides cycliques, d'acides nucléiques antisens, d'ARNi et de ribozymes, qui modulent l'activation des lymphocytes T par l'intermédiaire de la transduction des signaux associés à l'IL10-R et de l'IL10-R; ainsi que l'utilisation de profils d'expression et de compositions dans le diagnostic et le traitement associés aux maladies auto-immunes et aux greffes de tissus et d'organes.
PCT/US2002/031619 2001-10-03 2002-10-02 Il10-r : modulateurs de l'activation des lymphocytes WO2003029278A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341948A AU2002341948A1 (en) 2001-10-03 2002-10-02 Il10-r: modulators of lymphocyte activation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32721201P 2001-10-03 2001-10-03
US60/327,212 2001-10-03
US36203402P 2002-03-04 2002-03-04
US60/362,034 2002-03-04

Publications (2)

Publication Number Publication Date
WO2003029278A2 WO2003029278A2 (fr) 2003-04-10
WO2003029278A3 true WO2003029278A3 (fr) 2005-04-14

Family

ID=26985754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031619 WO2003029278A2 (fr) 2001-10-03 2002-10-02 Il10-r : modulateurs de l'activation des lymphocytes

Country Status (2)

Country Link
AU (1) AU2002341948A1 (fr)
WO (1) WO2003029278A2 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HO ET AL.: "Interleukin-10 and its receptor", THERAPY IMMUNOLOGY, vol. 1, 1994, pages 173 - 185 *
KOTENKO ET AL.: "Identification and functional characterization of a second chain of the interleukin-10 receptor complex", THE EMBO JOURNAL, vol. 16, no. 9, 1997, pages 5894 - 5903 *
O'FARRELL ET AL.: "IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and independent pathways", THE EMBO JOURNAL, vol. 17, no. 4, 1998, pages 1006 - 1018 *

Also Published As

Publication number Publication date
WO2003029278A2 (fr) 2003-04-10
AU2002341948A1 (en) 2003-04-14

Similar Documents

Publication Publication Date Title
WO2003094862A3 (fr) Arnt synthase utilisee comme modulateur de l'angiogenese
WO2004019893A3 (fr) Modulateurs d'angiogenese
WO2004039955A3 (fr) Modulateurs de l'angiogenese et de la tumorigenese
CY1108090T1 (el) Επαυξηση και αυξηση ογκου μαλακου ιστου και οστου χρησιμοποιωντας μυο-λαμβανομενα προγονα κυτταρα, συνθεσεις και θεραπειες αυτων
EP0701563A4 (fr) Transfert genique destine au traitement de tissus conjonctifs chez un mammifere hote
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2002085290A3 (fr) Proteines edg: modulateurs de l'activation et de la migration des lymphocytes
EP2105449A3 (fr) Agents antagonistes de liaison sélective de protéine de liaison d'ostéoprotégérine
DE69631544D1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
WO1999040197A3 (fr) Variants du facteur angiogenique de croissance cellulaire endotheliale vasculaire vegf
ATE323153T1 (de) Sphingosinekinase
DE69926764D1 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
WO2004039832A3 (fr) Peptides associes a la leptine
WO2002101071A3 (fr) Cd43: modulateurs de degranulation de mastocytes
BR0110190A (pt) Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele
WO2005069855A3 (fr) Modulateurs d'angiogenese
WO2002078610A3 (fr) Pak2: modulateurs de l'activation lymphocytaire
WO2003088910A3 (fr) Procedes de criblage de modulateurs du cycle cellulaire
WO2003029278A3 (fr) Il10-r : modulateurs de l'activation des lymphocytes
Assailly et al. Effect of weak inductively coupled pulsating currents on calcium uptake in embryonic chick tibia explants
ATE419389T1 (de) Sak: modulation der zellproliferation zur krebsbehandlung
WO2002101070A3 (fr) Integrine alpha 2: modulateurs de l'activation des lymphocytes
WO2004020979A3 (fr) Procedes de criblage de modulateurs du cycle cellulaire au moyen de composes de la cascade de ligature d'ubiquitine
WO2002085289A3 (fr) Modulateur de l'angiogenese
WO2002101072A3 (fr) Letm1 : modulateurs de la proliferation cellulaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP